Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$46.97 USD
-0.05 (-0.11%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $46.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth C Momentum B VGM
Zacks News
MannKind (MNKD) Looks Good: Stock Adds 5.6% in Session
by Zacks Equity Research
MannKind (MNKD) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Protagonist (PTGX) Begins Dosing in Phase I Study With PN-235
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doses the first patient in a phase I study on its oral IL-23 receptor antagonist, PN-235, being developed in collaboration with Janssen Biotech. Shares rise.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 65.57% and 245.11%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -3.51% and 63.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics' PTG-300 Gets FDA's Orphan Drug Tag
by Zacks Equity Research
The FDA bestows an orphan drug status on Protagonist Therapeutics' (PTGX) PTG-300 injection for treating patients with polycythemia vera. It is also being developed for hereditary hemochromatosis.
Company News for May 11, 2020
by Zacks Equity Research
Companies In The News Are: FTEK, PTGX, SXC, ZG
Why Did Protagonist Therapeutics (PTGX) Soar 83.7% Today?
by Madeleine Johnson
Shares of micro-cap biopharmaceutical company Protagonist Therapeutics (PTGX) soared on Friday, and were up over 90% at one point in afternoon trading.
Protagonist Therapeutics (PTGX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 1.56% and -48.21%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Protagonist Therapeutics (PTGX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist (PTGX) Starts Study on PTG-300 for Blood Disorder
by Zacks Equity Research
Protagonist's (PTGX) phase II study on PTG-300 will evaluate it as a potential treatment for hereditary hemochromatosis, a rare blood disorder, caused due to accumulation of iron.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 18.67% and -27.98%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Protagonist Therapeutics (PTGX) Q3 Earnings Expected to Decline
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -337.04% and -176.06%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 10.77% and -37.60%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Protagonist Therapeutics (PTGX) Q1 Earnings Expected to Decline
by Zacks Equity Research
Protagonist Therapeutics (PTGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of 5.00% and -3.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Protagonist Therapeutics (PTGX) Q3 Earnings Preview: What to Know Ahead of the Release
by Zacks Equity Research
Protagonist Therapeutics (PTGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Protagonist Therapeutics (PTGX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Protagonist Therapeutics (PTGX) delivered earnings and revenue surprises of -36.67% and 36.54%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Puma Biotech (PBYI) Q1 Loss Narrows, Sales Miss, Stock Down
by Zacks Equity Research
Puma Biotechnology (PBYI) Q1 loss per share is narrower than the Zacks Consensus Estimate while sales misses the same.
Infinity (INFI) Incurs In-Line Loss in Q1, Maintains View
by Zacks Equity Research
Infinity (INFI) reports in-line loss in Q1 and maintains its 2018 guidance.
Epizyme (EPZM) Reports Narrower-Than-Expected Loss in Q1
by Zacks Equity Research
Epizyme (EPZM) betters loss estimates in Q1 and expects to file a new drug application to the FDA for its lead pipeline candidate tazemetostat in fourth-quarter 2018.
Merrimack (MACK) Reports Wider-Than-Expected Loss in Q1
by Zacks Equity Research
Merrimack (MACK) reports wider-than-expected loss in the first quarter.